ESTTA Tracking number:
`
`Filing date:
`
`ESTTA1314032
`10/04/2023
`
`IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
`BEFORE THE TRADEMARK TRIAL AND APPEAL BOARD
`
`Notice of Opposition
`
`Notice is hereby given that the following party opposes registration of the indicated application.
`
`Opposer information
`
`Name
`
`Novocure GmbH
`
`Granted to date
`of previous ex-
`tension
`
`Address
`
`Attorney informa-
`tion
`
`10/04/2023
`
`20 VALLEY STREAM PKWY
`SUITE 300
`MALVERN, PA 19355
`UNITED STATES
`
`HARA K. JACOBS
`BALLARD SPAHR LLP
`1735 MARKET STREET 51ST FL.
`PHILADELPHIA, PA 19103
`UNITED STATES
`Primary email: tmdocketing@ballardspahr.com
`Secondary email(s): jacobsh@ballardspahr.com, sablee@ballardspahr.com,
`frankenfieldb@ballardspahr.com
`215.864.8209
`
`Docket no.
`
`00267688
`
`Applicant information
`
`Application no.
`
`88221050
`
`Opposition filing
`date
`
`Applicant
`
`10/04/2023
`
`Publication date
`
`06/06/2023
`
`Opposition period
`ends
`
`10/04/2023
`
`Septodont Holding SAS
`58, RUE DU PONT DE CRETEIL
`SAINT-MAUR-DES FOSSES, Cedex9410
`FRANCE
`
`Goods/services affected by opposition
`
`Class 005. First Use: None First Use In Commerce: None
`All goods and services in the class are opposed, namely: Pharmaceutical preparations, namely, acne
`medication, allergy medication, antacids, anthelmintics, antiarrhythmics, antibiotic creams and oint-
`ments, antibiotics, anticoagulants, anticonvulsants, antidepressants, antiemetics, antiflatulants, anti-
`histamines, antihypertensives anti-infectives, anti-inflammatories, antiparasites, antivirals, burn relief
`medication, calcium channel blockers, central nervous system depressants, central nervous system
`stimulants, cough treatment medication, diarrhea medication, fungal medications, gastro-intestinal
`pharmaceutical preparations, glaucoma agents, hydrocortisone, hypnotic agents, sedatives, pain re-
`lief medication, and topical and injectable pharmaceutical preparations for dental, endodontic and
`periodontal disorders; anti-epileptic pharmaceutical preparations; bismuth preparations for pharma-
`ceutical use; bromine for pharmaceutical purposes; cardiovascular pharmaceutical preparations;
`frostbite salve for pharmaceutical purposes; guaiacol for pharmaceutical purposes; intravenous fluids
`used for rehydration, nutrition and the delivery of pharmaceutical preparations; inhaled pharmaceutic-
`
`

`

`al preparations for the treatment of respiratory diseases and disorders; injectable pharmaceutical
`contraceptives; pharmaceutical anti-allergic preparations and substances; pharmaceutical for the
`treatment of erectile dysfunction; pharmaceutical hormonal preparations, namely, corticosteroids,
`hormone replacement therapy preparations, oral contraceptives, thyroid hormone preparations; phar-
`maceutical preparations and substances for the treatment of gastro-intestinal diseases; pharmaceut-
`ical preparations for the treatment of bone fractures; pharmaceutical preparations for inhalation for
`the treatment of pulmonary hypertension; pharmaceutical preparations for ocular or intraocular sur-
`gery; pharmaceutical preparations for reducing cholesterol; pharmaceutical preparations for the pre-
`vention of osteoporosis; pharmaceutical preparations for the relief of pain; pharmaceutical prepara-
`tions for the treatment of acne; pharmaceutical preparations for the treatment of bacterial skin infec-
`tions, fungal skin infections, viral skin infections and parasitic skin infections; pharmaceutical prepara-
`tions for the treatment of allergies; pharmaceutical preparations for the treatment of blood disorders;
`pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treat-
`ment of cardiovascular diseases; pharmaceutical preparations for the treatment of carpal tunnel syn-
`drome; pharmaceutical preparations for the treatment of chronic pain; pharmaceutical preparations
`for the treatment of cranial or facial nerve disorders; pharmaceutical preparations for the treatment of
`degenerative nerve diseases and disorders, namely, Alzheimer's disease, Parkinson's disease, Hunt-
`ington's disease and multiple sclerosis; pharmaceutical preparations for the treatment of dental and
`oral diseases; pharmaceutical preparations for the treatment of diseases, disorders and infections of
`the endocrine system, namely, growth and thyroid disorders; pharmaceutical preparations for the
`treatment of diseases, disorders and infections of the spinal cord systems and related cartilage and
`tissue; pharmaceutical preparations for the treatment of drug and alcohol abuse; pharmaceutical pre-
`parations for the treatment of gastro-intestinal diseases; pharmaceutical preparations for the treat-
`ment of genito-urinary and pelvic diseases, disorders and infections, namely, infertility, sexually trans-
`mitted diseases, incontinence and sexual dysfunction; pharmaceutical preparations for the treatment
`of genitourinary diseases, namely, urological diseases, infertility, sexually transmitted diseases, in-
`flammatory pelvic diseases; pharmaceutical preparations for the treatment of glaucoma; pharmaceut-
`ical preparations for the treatment of headaches; pharmaceutical preparations for the treatment of hy-
`percholesteremia; pharmaceutical preparations for the treatment of hyperlipidemia; pharmaceutical
`preparations for the treatment of immunologic diseases, namely, autoimmune diseases, immunologic
`deficiency syndromes; pharmaceutical preparations for the treatment of infectious diseases, namely,
`respiratory infections, eye infections; pharmaceutical preparations for the treatment of inflammatory
`connective tissue diseases and injuries; pharmaceutical preparations for the treatment of inflammat-
`ory diseases, namely, inflammatory bowel diseases, inflammatory connective tissue diseases; phar-
`maceutical preparations for the treatment of inflammatory muscle diseases and disorders; pharma-
`ceutical preparations for the treatment of metabolic diseases and disorders, namely, gout, osteoarth-
`ritis, muscular dystrophy, anemia; pharmaceutical preparations for the treatment of metabolic dis-
`orders, namely, bulimia nervosa, anorexia, and hypothyroidism; pharmaceutical preparations for the
`treatment of migraine; pharmaceutical preparations for the treatment of motion sickness; pharma-
`ceutical preparations for the treatment of multiple sclerosis; pharmaceutical preparations for the treat-
`ment of myalgia and neuralgia; pharmaceutical preparations for the treatment of neurological dis-
`eases, namely, Alzheimer's, Huntington's Disease, cerebral palsy; pharmaceutical preparations for
`the treatment of neurological disorders, namely, brain injury, spinal cord injury, seizure disorders;
`pharmaceutical preparations for the treatment of neuromuscular diseases and disorders, namely,
`cerebrovascular accident (stroke), Parkinson's disease, multiple sclerosis, myasthenia gravis, Hunt-
`ington's disease; pharmaceutical preparations for the treatment of oncological diseases and dis-
`orders; pharmaceutical preparations for the treatment of ophthalmological diseases and disorders;
`pharmaceutical preparations for the treatment of physical and psychological addictions, namely,
`gambling addiction, eating disorders and addictions, nicotine addiction, Internet addiction, drug addic-
`tion; pharmaceutical preparations for the treatment of psychiatric and other brain diseases and dis-
`orders, namely, anxiety, mood disorders, schizophrenia, cognitive and bipolar disorders, epilepsy,
`Alzheimer's, cerebral palsy, Parkinson's disease, multiple sclerosis; pharmaceutical preparations for
`the treatment of psychiatric diseases, namely, mood disorders, anxiety disorders, cognitive disorders,
`schizophrenia; pharmaceutical preparations for the treatment of respiratory diseases, disorders and
`infections; pharmaceutical preparations for the treatment of skin irritations, namely, bee stings, sun-
`burn, rashes, sores, corns, calluses, and acne; pharmaceutical preparations for the treatment of
`smoking cessation; pharmaceutical preparations for the treatment of the central nervous system,
`namely, central nervous system infections, brain diseases, central nervous system movement dis-
`orders, ocular motility disorders, spinal cord diseases; pharmaceutical preparations for the treatment
`of the central nervous system, namely, encephalitis, epilepsy, Alzheimer's, cerebral palsy, Parkin-
`
`

`

`son's disease; pharmaceutical preparations for the treatment of the diseases, disorders and infec-
`tions of the central nervous system, namely, brain, movement, ocular motility and spinal cord dis-
`eases; pharmaceutical preparations for the treatment of the musculoskeletal system, namely, con-
`nective tissue diseases, bone diseases, spinal diseases, back pain, fractures, sprains, cartilage injur-
`ies; pharmaceutical preparations for the treatment of the respiratory system; pharmaceutical prepara-
`tions for the treatment of varicose veins; pharmaceutical preparations for the treatment of vascular
`diseases; pharmaceutical preparations for the treatment of viral diseases, namely, herpes, hepatitis,
`Acquired Immune Deficiency Syndrome (AIDS); pharmaceutical preparations for treating allergic rhin-
`itis and asthma; pharmaceutical preparations for treating asthma; pharmaceutical preparations for
`treating dandruff; pharmaceutical preparations for use in dermatology, namely, dermatitis, skin pig-
`mentation diseases, sexually transmitted diseases; pharmaceutical preparations for use in discour-
`aging the smoking habit; pharmaceutical preparations for use in gastroenterology; pharmaceutical
`preparations for use in ocular disorders; pharmaceutical preparations for use in oncology; pharma-
`ceutical preparations for use in ophthalmology; pharmaceutical preparations for wounds; pharma-
`ceutical preparations against dry skin caused by pregnancy; pharmaceutical preparations for hydrat-
`ing the skin during pregnancy; pharmaceutical preparations for ophthalmological use; pharmaceutical
`preparations for the treatment of cancer; pharmaceutical preparations for treating respiratory dis-
`eases; pharmaceutical solutions used in dialysis; radioactive pharmaceutical preparations for in vivo
`diagnostic or therapeutic use; sunburn preparations for pharmaceutical purposes; synthetic peptides
`for the treatment of all of the foregoing diseases and conditions; disinfection systems, namely, all-
`purpose disinfectants
`
`Class 010. First Use: None First Use In Commerce: None
`All goods and services in the class are opposed, namely: Drug delivery systems, namely, needles,
`syringes, nasal spray bottles, injection devices, oral and nasal inhalation devices, patch pumps, and
`anesthetic delivery apparatus for medical purposes, but not for use in the fields of diabetes and
`obesity
`
`Class 035. First Use: None First Use In Commerce: None
`All goods and services in the class are opposed, namely: Business consulting services relating to
`pharmaceutical manufacturing, clinical evaluation and testing, regulatory registration, stability studies,
`method development, formal stability, registration batches and commercial production; clinical trial
`services, namely, business and information management of clinical studies to fast track drug
`products to market
`
`Grounds for opposition
`
`Priority and likelihood of confusion
`
`Trademark Act Section 2(d)
`
`Marks cited by opposer as basis for opposition
`
`U.S. registration
`no.
`
`5616214
`
`Register
`
`Principal
`
`Registration date
`
`11/27/2018
`
`Application date
`
`04/05/2018
`
`Foreign priority
`date
`
`NONE
`
`Word mark
`
`Design mark
`
`Description of
`mark
`
`Goods/services
`
`NOVOCURE
`
`NONE
`
`Class 010. First use: First Use: Dec 2003 First Use In Commerce: Jul 2006
`Medical device that delivers tumor treating fields, in the nature of electrical
`fields, to treat solid tumor cancers
`
`U.S. registration
`no.
`
`5913293
`
`Register
`
`Principal
`
`Application date
`
`04/15/2019
`
`Registration date
`
`11/19/2019
`
`Foreign priority
`
`NONE
`
`

`

`Word mark
`
`Design mark
`
`Description of
`mark
`
`Goods/services
`
`NOVOCURE
`
`date
`
`The mark consists of the word "novocure" in lower case letters, the first 3 and
`last 3 letters in light blue, and the o and c in the center of the word in light purple
`and partially overlapping each other.
`
`Class 010. First use: First Use: Sep 2016 First Use In Commerce: Sep 2016
`Medical device that delivers tumor treating fields, in the nature of electrical
`fields, to treat solid tumor cancers
`Class 041. First use: First Use: May 16, 2015 First Use In Commerce: May 16,
`2015
`Training services in the use and operation of a medical device that delivers tu-
`mor treating fields, in the nature of electrical fields, to treat solid tumor cancers
`and consultation relating thereto
`
`U.S. application/ registration
`no.
`
`Register
`
`Registration date
`
`Mark
`
`Goods/services
`
`Application date
`
`NONE
`
`NONE
`
`NONE
`
`NONE
`
`NOVOCURE
`
`Providing medical and scientific research information in the field of
`medical devices and clinical trials
`
`Attachments
`
`NOVOCOL PHARMA NOO final.pdf(593380 bytes )
`
`Signature
`
`/Hara K. Jacobs/
`
`Name
`
`Date
`
`HARA K. JACOBS
`
`10/04/2023
`
`

`

`
`
`IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
`BEFORE THE TRADEMARK TRIAL AND APPEAL BOARD
`
`Opposition No. ________________
`
`Serial No. 88/221,050
`
`Mark: NOVOCOL PHARMA
`
`: : : : : : : : : :
`
`Novocure GmbH,
`
`
`Opposer,
`
`
`
`v.
`
`
`Septodont Holding SAS,
`
`
`Applicant.
`
`
`
`
`NOTICE OF OPPOSITION
`
`In the matter of the application of Septodont Holding SAS (“Applicant”) for registration
`
`of the mark NOVOCOL PHARMA, Application Serial No. 88/221,050 (“Application”), filed
`
`December 7, 2018, and published for opposition in the Official Gazette on June 6, 2023:
`
`Novocure GmbH, a Swiss corporation having a principal place of business at Park 6,
`
`Root D4, Switzerland (“Opposer”), believes that it will be damaged by the registration of the
`
`mark shown in the above-identified Application in Classes 5, 10, and 35, and hereby opposes the
`
`same. The grounds for opposition are as follows:
`
`1.
`
`Opposer is a pioneering oncology company in the field of solid tumor treatment.
`
`Opposer develops and sells novel cancer treatments, and offers these therapies and related
`
`services under its NOVOCURE® mark.
`
`2.
`
`Opposer is the owner of federal trademark registrations for Opposer’s
`
`NOVOCURE® Mark (the “NOVOCURE® Marks”) for its cancer treatment devices and related
`
`training and consultation services, as summarized in the below table (collectively, with the
`
`services discussed in Paragraph 3, “Opposer’s Goods and Services”). Attached hereto as
`
`Exhibit A are printouts from the electronic database records of the USPTO showing the current
`
`status and title of these registrations (“Opposer’s Registrations”).
`
`
`
`
`
`

`

`
`
`Mark
`
`NOVOCURE
`
`
`Registration
`No.
`
`5616214
`
` 5913293
`
`Registration
`Date
`
`Nov. 27, 2018
`
`
`Nov. 19, 2019
`
`
`Goods
`
`Class 10: Medical device that delivers tumor
`treating fields, in the nature of electrical fields,
`to treat solid tumor cancers (Date of first use:
`December 2003; Date of first use in commerce:
`July 2006)
`
`Class 10: Medical device that delivers tumor
`treating fields, in the nature of electrical fields,
`to treat solid tumor cancers (Date of first use:
`Sept. 2016)
`
`Class 41: Training services in the use and
`operation of a medical device that delivers
`tumor treating fields, in the nature of electrical
`fields, to treat solid tumor cancers and
`consultation relating thereto (Date of first use:
`May 16, 2015)
`
`
`
`3.
`
`Opposer has used the mark NOVOCURE in connection with providing medical
`
`and scientific research information in the field of medical devices and clinical trials since at least
`
`as early as 2006 (herein “NOVOCURE Common Law Mark”).
`
`4.
`
`5.
`
`Opposer’s Registrations are valid and subsisting.
`
`Opposer’s use of the NOVOCURE® Marks and NOVOCURE Common Law
`
`Mark has been continuous, exclusive, and commercially significant since at least its date of first
`
`use in connection with Opposer’s Goods and Services.
`
`6.
`
`Opposer’s NOVOCURE® Marks and NOVOCURE Common Law Mark have
`
`been valid and in continuous use since at least their respective dates of first use and have not
`
`been abandoned.
`
`7.
`
`Opposer’s NOVOCURE® Marks and NOVOCURE Common Law Mark are
`
`inherently distinctive as applied to Opposer’s Goods and Services.
`
`8.
`
`Because of the substantial investment of time and resources nationally to market,
`
`promote, and advertise Opposer’s NOVOCURE® Marks and NOVOCURE Common Law
`
`
`
`2
`
`

`

`
`
`Mark, consumers have come to associate Opposer’s NOVOCURE® Marks and NOVOCURE
`
`Common Law Mark exclusively with Opposer and Opposer’s Goods and Services.
`
`9.
`
`By virtue of Opposer’s continuous use in commerce of Opposer’s NOVOCURE®
`
`Marks and NOVOCURE Common Law Mark in connection with Opposer’s Goods and Services,
`
`such goods and services have become favorably known to the relevant trade and public under
`
`Opposer’s NOVOCURE® Marks.
`
`10.
`
`Applicant seeks to register the alleged mark NOVOCOL PHARMA for, inter
`
`alia, “pharmaceutical preparations for the treatment of oncological diseases and disorders;
`
`pharmaceutical preparations for use in oncology; pharmaceutical preparations for the relief of
`
`pain; pharmaceutical preparations for the treatment of chronic pain; radioactive
`
`pharmaceutical preparations for in vivo diagnostic or therapeutic use” in International Class 5,
`
`“Drug delivery systems, namely, needles, syringes, nasal spray bottles, injection devices, oral
`
`and nasal inhalation devices, patch pumps, and anesthetic delivery apparatus for medical
`
`purposes, but not for use in the fields of diabetes and obesity” in Class 10, and “Business
`
`consulting services relating to pharmaceutical manufacturing, clinical evaluation and testing,
`
`regulatory registration, stability studies, method development, formal stability, registration
`
`batches and commercial production; clinical trial services, namely, business and information
`
`management of clinical studies to fast track drug products to market” in Class 35, as evidenced
`
`by the publication of said mark in the Official Gazette on June 6, 2023.
`
`11.
`
`The Application herein opposed was filed on December 7, 2018 based on Section
`
`44(e) of the Trademark Act, 15 US.C. § 1126(e), claiming priority to a Canadian trademark
`
`registration with an application filing date of November 22, 2018.
`
`12.
`
`Opposer’s dates of first use for Opposer’s NOVOCURE® Marks and
`
`NOVOCURE Common Law Mark and Opposer’s application and registration dates for
`
`Opposer’s NOVOCURE® Marks precede the priority date for the Application.
`
`13.
`
`The NOVOCOL PHARMA mark in the Application is likely to cause confusion
`
`with Opposer’s NOVOCURE® Marks and NOVOCURE Common Law Mark and is thereby
`
`
`
`3
`
`

`

`
`
`causing harm to Opposer. Opposer, therefore, has a real interest in opposing the NOVOCOL
`
`PHARMA Application and standing to bring this action.
`
`14.
`
`In the Application for the goods and services herein opposed, there are no
`
`restrictions on trade channels, so it must be presumed that the goods and services identified in
`
`the Application will travel through all trade channels appropriate for goods and services of that
`
`type.
`
`15.
`
`Upon information and belief, the goods and services recited in the Application
`
`and Opposer’s Goods and Services are intended to be marketed through overlapping channels of
`
`trade and are intended to be offered to overlapping classes of consumers, including but not
`
`limited to healthcare professionals, cancer patients, and the families and loved ones of cancer
`
`patients.
`
`16.
`
`Applicant’s alleged mark NOVOCOL PHARMA is confusingly similar to
`
`Opposer’s NOVOCURE® Marks and NOVOCURE Common Law Mark because the marks are
`
`visually and aurally similar.
`
`17.
`
`Applicant’s alleged mark NOVOCOL PHARMA is confusingly similar to
`
`Opposer’s NOVOCURE® Marks and NOVOCURE Common Law Mark because the marks
`
`have a similar overall commercial impression.
`
`18.
`
`The goods and services identified in Classes 5, 10, and 35 in the Application are
`
`highly related to Opposer’s Goods and Services, as both parties’ goods and services are directed
`
`to the treatment of cancer and are directed to consumers and healthcare professionals in the
`
`cancer treatment space.
`
`19.
`
`Applicant’s alleged NOVOCOL PHARMA mark as applied to the goods and
`
`services identified in the Application so resembles Opposer’s NOVOCURE® Marks and
`
`NOVOCURE Common Law Mark as applied to Opposer’s Goods and Services that it is likely to
`
`cause confusion, mistake, and/or deception.
`
`20.
`
`If Applicant is permitted to register the alleged mark NOVOCOL PHARMA for
`
`the goods and services recited in the Application, confusion in the relevant trade and public is
`
`
`
`4
`
`

`

`
`
`likely to result, which will damage and injure Opposer.
`
`21.
`
`Any defect, objection to, or fault found with Applicant’s goods and services under
`
`Applicant’s alleged NOVOCOL PHARMA mark would necessarily reflect on and seriously
`
`injure the reputation that Opposer has established for its goods and business.
`
`22.
`
`If Applicant is granted a registration for the mark herein opposed, it would obtain
`
`thereby at least a prima facie exclusive right to use the mark in connection with the goods and
`
`services recited in the Application. Such registration would be a source of damage and injury to
`
`Opposer for the reasons listed above.
`
`WHEREFORE, Novocure GmbH prays that registration of the mark of Application Serial
`
`No. 88/221,050 in Classes 15, 10, and 35 be refused and that this Opposition be sustained.
`
`
`
`
`
`
`
`
`
`October 4, 2023
`
`Respectfully submitted,
`
`
`
`
`
`
`
`
`
`
`By:
`
`
`/s/ Hara K. Jacobs
`Hara K. Jacobs
`Eric M. Sable
`BALLARD SPAHR LLP
`1735 Market Street, 51st Floor
`Philadelphia, PA 19103-7599
`Telephone: 215.864.8209
` Attorneys for Opposer
`
`5
`
`

`

`Exhibit A
`Exhibit A
`
`

`

`United States Patent and Trademark Office
`
`Home|Site Index|Search|FAQ|Glossary|Contacts|eBusiness|eBiz alerts|News
` Trademarks > Trademark Electronic Search System (TESS)
`
`TESS was last updated on Wed Oct 4 03:47:22 EDT 2023
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Logout Please logout when you are done to release system resources allocated for you.
`
`Start List At:
`
`OR Jump to record:
`
`Record 3 out of 5
`
`
`
`
`
` ( Use the "Back" button of the Internet Browser to return to TESS)
`
`Word Mark
`Goods and Services
`
`Standard Characters
`Claimed
`Mark Drawing Code
`Serial Number
`Filing Date
`Current Basis
`Original Filing Basis
`Published for
`Opposition
`Registration Number
`Registration Date
`Owner
`
`NOVOCURE
`IC 010. US 026 039 044. G & S: Medical device that delivers tumor treating fields, in the nature of electrical fields, to treat solid tumor
`cancers. FIRST USE: 20031200. FIRST USE IN COMMERCE: 20060700
`
`(4) STANDARD CHARACTER MARK
`87864623
`April 5, 2018
`1A
`1A
`September 11, 2018
`
`5616214
`November 27, 2018
`(REGISTRANT) NovoCure Limited CORPORATION JERSEY Second Floor, No. 4 The Forum Grenville Street St Helier JERSEY
`JE24UF
`
`(LAST LISTED OWNER) NOVOCURE GMBH CORPORATION SWITZERLAND PARK 6 ROOT D4 SWITZERLAND
`Assignment Recorded ASSIGNMENT RECORDED
`Attorney of Record
`Hara K. Jacobs
`Type of Mark
`TRADEMARK
`Register
`PRINCIPAL
`Live/Dead Indicator
`LIVE
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`|.HOME | SITE INDEX| SEARCH | eBUSINESS | HELP | PRIVACY POLICY
`
`

`

`United States Patent and Trademark Office
`
`Home|Site Index|Search|FAQ|Glossary|Contacts|eBusiness|eBiz alerts|News
` Trademarks > Trademark Electronic Search System (TESS)
`
`TESS was last updated on Wed Oct 4 03:47:22 EDT 2023
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Logout Please logout when you are done to release system resources allocated for you.
`
`Start List At:
`
`OR Jump to record:
`
`Record 2 out of 5
`
`
`
`
`
` ( Use the "Back" button of the Internet Browser to return to TESS)
`
`Word Mark
`Goods and
`Services
`
`NOVOCURE
`IC 010. US 026 039 044. G & S: Medical device that delivers tumor treating fields, in the nature of electrical fields, to treat solid tumor
`cancers. FIRST USE: 20160900. FIRST USE IN COMMERCE: 20160900
`
`IC 041. US 100 101 107. G & S: Training services in the use and operation of a medical device that delivers tumor treating fields, in the
`nature of electrical fields, to treat solid tumor cancers and consultation relating thereto. FIRST USE: 20150516. FIRST USE IN COMMERCE:
`20150516
`(5) WORDS, LETTERS, AND/OR NUMBERS IN STYLIZED FORM
`
`88385697
`April 15, 2019
`1A
`1A
`
`September 3, 2019
`
`5913293
`
`Mark Drawing
`Code
`Serial Number
`Filing Date
`Current Basis
`Original Filing
`Basis
`Published for
`Opposition
`Registration
`Number
`Registration Date November 19, 2019
`Owner
`(REGISTRANT) NOVOCURE GMBH GESELLSCHAFT MIT BESCHRÄ NKTER HAFTUNG (G SWITZERLAND PARK 6 ROOT D4
`SWITZERLAND 6039
`ASSIGNMENT RECORDED
`
`Assignment
`Recorded
`Attorney of
`Record
`Prior
`Registrations
`Description of
`Mark
`Type of Mark
`Register
`Live/Dead
`Indicator
`
`Hara K. Jacobs
`
`5616214
`
`The color(s) light blue and light purple is/are claimed as a feature of the mark. The mark consists of the word "novocure" in lower case letters,
`the first 3 and last 3 letters in light blue, and the o and c in the center of the word in light purple and partially overlapping each other.
`TRADEMARK. SERVICE MARK
`PRINCIPAL
`LIVE
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`|.HOME | SITE INDEX| SEARCH | eBUSINESS | HELP | PRIVACY POLICY
`
`

`

`